Amazon Biotech

Amazon Biotech is a clinical-stage biopharmaceutical company specializing in the development of botanical-based therapeutics for viral infections. The company's lead candidate, AMZ-001, is a complex botanical drug that has been evaluated in Phase 2 clinical trials for the treatment of HIV-1 infection. Amazon Biotech's approach focuses on leveraging the synergistic effects of natural compounds to inhibit viral replication and modulate immune responses. In addition to its work in HIV, the company has explored the potential of its pipeline candidates in addressing other viral threats, including SARS-CoV-2. The company operates as an independent entity focused on providing novel treatment options derived from natural sources.